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Abstract
Background: Hundreds of genes that are causally implicated in oncogenesis have been found and collected in
various databases. For efficient application of these abundant but diverse data sources, it is of fundamental
importance to evaluate their consistency.
Results: First, we showed that the lists of cancer genes from some major data sources were highly inconsistent in
terms of overlapping genes. In particular, most cancer genes accumulated in previous small-scale studies could not
be rediscovered in current high-throughput genome screening studies. Then, based on a metric proposed in this
study, we showed that most cancer gene lists from different data sources were highly functionally consistent.
Finally, we extracted functionally consistent cancer genes from various data sources and collected them in our
database F-Census.
Conclusions: Although they have very low gene overlapping, most cancer gene data sources are highly consistent
at the functional level, which indicates that they can separately capture partial genes in a few key pathways
associated with cancer. Our results suggest that the sample sizes currently used for cancer studies might be
inadequate for consistently capturing individual cancer genes, but could be sufficient for finding a number of
cancer genes that could represent functionally most cancer genes. The F-Census database provides biologists with
a useful tool for browsing and extracting functionally consistent cancer genes from various data sources.
Background
Cancer is an extremely heterogeneous disease that is
induced by mutations or other alterations in many
genes [1,2]. Identification of genes that are causally
implicated in oncogenesis is of basic importance for pre-
dicting novel cancer genes [3-6], and studying their evo-
lutionary conservation [6,7], biological network features
[4,8] and functions [9-11]. It can also provide valuable
biomarkers for cancer diagnosis and drug development
[2,11]. Until now, hundreds of cancer genes that have
been found in small-scale experiments have been col-
lected in various databases such as Cancer Gene Census
(CGC) [12], Online Mendelian Inheritance in Man
(OMIM) [13], and many others [14-17]. Recently, by
high-throughput somatic mutational screening of cancer
genomes [18-24], hundreds of new cancer genes that
carry driver mutations are being identified rapidly.
These increasingly abundant data provide us with an
excellent opportunity to understand the underlying
complex mechanisms of oncogenesis.
Nevertheless, we face new challenges to interpret and
apply these abundant yet diverse data sources efficiently.
In particular, it is important to evaluate the consistency
and reliability of the information from different data
sources. In this work, we analyzed six lists of cancer
genes separately from six major databases [12-17] and
two lists of candidate cancer genes identified by two
types of high-throughput techniques [19,20,22,23,25,26].
First, we showed that these gene lists were highly incon-
sistent in terms of overlapping genes, which reflected
partially their various types of cancer and mutations. In
particular, most cancer genes accumulated in small-scale
experiments could not be reproduced in current high-
throughput mutational screening of cancer genomes,
even when comparing cancer type-specific genes. This
suggests that the sample sizes used in the small-scale
studies or high-throughput genome screening might
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are causally related to cancers with extremely heteroge-
neous genetic mechanisms.
On the other hand, various gene lists might capture
separately different genes in a few functional pathways
that are related to human cancer [1,18,20,21,27-29].
Based on protein-protein interaction (PPI) data, we
introduced the POGF (Percentage of Overlapping Genes
Functionally related) metric to evaluate the functional
consistency of gene lists, and found that most of them
were actually highly functionally consistent. Specifically,
most cancer genes accumulated in previous small-scale
studies could be functionally reproduced in current
high-throughput studies.
The CGC database is the most widely utilized can-
cer gene data source [3-6,8,11,22,23], therefore, we
used it as a benchmark for evaluating and selecting
functionally consistent cancer genes from other data
sources. We found that the selected genes were more
significantly enriched in cancer pathways than the
rest of the genes. Finally, we developed the database
F-Census for collecting functionally consistent cancer
genes from various data sources http://bioinfo.hrbmu.
edu.cn/fcensus/.
Methods
Cancer gene lists
We analyzed six databases of cancer genes whose altera-
tions might play causative roles in carcinogenesis (Table
1). We also analyzed a list of 491 cancer genes provided
by mutational screening in cancer genomes for four can-
cer types [19,20,22,23] and another list of 645 cancer
genes identified by retroviral insertional mutagenesis
screening [25,26].
PPI and Gene Ontology (GO) data
The PPI data were derived from the Human Protein
Reference Database (HPRD, release 7) [30], which con-
tains 34 998 interactions that involve 9303 proteins
after removing self-interactions, including 13 080 inter-
actions between 6311 proteins derived from high-
throughput yeast two-hybrid experiments. The GO
annotation data [31] were downloaded on September
1, 2008.
Evaluating the consistency of gene lists by POG scores
The POG (Percentage of Overlapping Genes) metric was
used to evaluate the consistency of two gene lists
[32-34]. If list 1 with length l1 a n dl i s t2w i t hl e n g t hl2
have m overlapping genes, then the score from list 1 to
list 2 is POG12 = m/l1 and the score from list 2 to list 1
is POG21 = m/l2. To reduce the effect of list lengths on
the POG scores, we also calculated the normalized
scores as follows [33]:
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where E(POG12)a n dE(POG21)a r et h eP O Gs c o r e s
expected by random chance, which are estimated sepa-
rately as the average of the scores for 10 000 pairs of
Table 1 The eight cancer gene lists analyzed in this paper
Short names Full names and URLs References No. of genes
CGC Cancer Gene Census
http://www.sanger.ac.uk/genetics/CGP/Census/
[12] 377*(328**)
OMIM
a Online Mendelian Inheritance in Man
http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim
[13] 244 (217)
Reviews
b CancerGenes database
http://cbio.mskcc.org/CancerGenes/Select.action
[14,28,50] 289(261)
AGCOH Atlas of Genetics and Cytogenetics in Oncology and Haematology
http://atlasgeneticsoncology.org/
[17] 727(619)
TGDBs The Tumor Gene Family of Databases
http://www.tumor-gene.org/Oral/oral.html
[16,51,52] 314(295)
TSGDB Tumor suppressor gene database
http://www.cise.ufl.edu/~yy1/HTML-TSGDB/Homepage.html
[15] 148(109)
H-list Candidate cancer genes provided by genome mutation scans [19,20,22,23] 491(316)
R-list Candidate cancer genes identified by retroviral insertional mutagenesis screens
http://RTCGD.ncifcrf.gov
http://mutapedia.nki.nl
[25,26] 646(496)
Total 2105 (1594)
Note: *the numbers of genes compiled in the original datasets; **the numbers of genes with PPI data.
a cancer genes were extracted from OMIM as did in [53].
b
cancer genes from two Reviews which are collected in the CancerGenes database [2850].
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from the human genome.
Evaluating the functional consistency of gene lists at the
network level
We proposed to evaluate the functional consistency of
two gene lists by taking into account functionally
similar genes between the lists. First, a gene was
d e f i n e dt ob ef u n c t i o n a l l ys i m i l a rt oag e n el i s ti fi t s
PPI links to the genes in the list were significantly
more than expected by random chance (P <0 . 0 5 ) .
Here, a PPI link between two genes means that the
two genes interact with each other or share at least
one neighbour in the PPI network [35-37]. Suppose a
gene has k PPI links to the M g e n e si nal i s t ,t h e nt h e
probability of observing at least k links by random
chance can be calculated by the hypergeometric prob-
ability model:
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where N i st h en u m b e ro fa l lt h ep o s s i b l el i n k s
between this gene and other genes in the PPI network,
and n is the observed number.
Then, we proposed the POGF score between gene list
1 with length l1 and list 2 with length l2 as follows:
POGF O Of l 12 12 1  () / (4)
POGF O Of l 21 21 2  () / (5)
where O is the number of genes shared by the two
lists, and Of12 (or Of21) is the number of genes in list 1
(or list 2) not shared by but functionally similar to
genes in list 2 (or list 1).
To remove the effect of list lengths, we normalized the
POGF scores for the two lists as follows [33]:
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where E(POGF12)a n dE(POGF21) are the scores
expected by random chance for two gene lists (with
length l1 and l2), which are estimated separately as the
average of the scores of 10 000 pairs of gene lists (with
length l1 and l2) extracted randomly from all the genes
in the PPI network.
Statistical significance of a consistency score
To evaluate the significance of an observed POG (or
POGF) score between two lists (with length l1 and l2),
we selected randomly a pair of gene lists (with length l1
and l2) and calculated the score by the same method.
This process was repeated 10 000 times. The signifi-
cance (P value) of the score was calculated as the per-
centage of the random scores that were larger than the
observed score. The P value of a nPOG or nPOGF score
is the same as that of the corresponding POG or POGF
score because the E(POG) or E(POGF) that is used to
normalize the POG or POGF score is a constant [33].
Selecting functionally consistent cancer genes
The CGC database comprises cancer genes with rela-
tively stringent criteria. Therefore, we filtered other gene
lists according to their functional similarity to the genes
included in the CGC database. A gene was selected if its
functional links to genes from CGC were significantly
more than expected by random chance, with the P value
calculated by formula (3) and corrected by the FDR con-
trol [38]. Then, for the selected genes and the remaining
ones, respectively, we calculated the probabilities of
their enrichment in each of the 10 cancer pathways
described in the Cancer Cell Map database [39], by the
hypergeometric distribution model.
Results
Consistency between gene lists in terms of gene
overlapping
CGC is the most widely utilized cancer gene data
source in various applications [3-6,8,11,22,23], there-
f o r e ,w eu s e di ta sab a s e l i n ef o rt h ec o m p a r i s o n .T h e
POG (nPOG) score from Reviews to CGC was 0.84
(0.84) and 0.65 (0.64) from CGC to Reviews. However,
a ss h o w ni nF i g u r e1 A ,m o s to t h e rg e n el i s t sw e r e
highly inconsistent with CGC. The POG (nPOG) score
from OMIM to CGC was 0.53 (0.53) and 0.34 (0.34) in
the other direction. Notably, 55% of the genes in CGC
were labelled with leukaemia/lymphoma, whereas only
about 21% of the genes in OMIM were associated with
this cancer. The POG (nPOG) score from AGCOH to
CGC was 0.36 (0.35) and 0.70 (0.69) from CGC to
AGCOH. Among the 263 genes shared by these two
databases, 152 (60%) were associated with haematolo-
gical cancer. The POG (nPOG) score from TGDBs to
CGC was 0.26 (0.25) and 0.22 (0.21) from CGC to
TGDBs, which only included genes discovered in six
epithelial cancer types. TSGDB only included tumor
suppressor genes, therefore, the POG (nPOG) score
from it to CGC was only 0.14 (0.12) and 0.05 (0.05) in
the other direction.
The above results showed that these lists of cancer
genes were highly inconsistent in terms of gene
Gong et al. BMC Bioinformatics 2010, 11:76
http://www.biomedcentral.com/1471-2105/11/76
Page 3 of 8overlapping. However, all the observed POG and nPOG
scores were significantly larger than the scores expected
by random chance (P < 1.0 E-04).
Functional consistency between gene lists
Although different gene lists are inconsistent in terms of
overlapping genes, they could each capture different
genes in the same pathways associated with cancer. For
example, as shown in Figure 2, different lists of cancer
genes covered various genes in the Wnt and EGRF1
pathways. Next, we evaluated the functional consistency
of the gene lists based on the POGF (nPOGF) scores.
A ss h o w ni nF i g u r e1 A( b a r sa b o v et h exa x i s ) ,t h e
POGF (nPOGF) scores from Reviews, OMIM, AGCOH,
TGDBs and TSGDB to CGC were 0.97 (0.97), 0.90
(0.89), 0.80 (0.79), 0.82 (0.81) and 0.72 (0.71), respec-
tively. In another direction, the POGF (nPOGF) scores
from CGC to the other lists were as high as 0.92 (0.91),
0.87 (0.87), 0.94 (0.94), 0.83 (0.82) and 0.60 (0.59). From
TGDBs to CGC, although the POG (nPOG) score was
only 0.26 (0.25), the POGF (nPOGF) score was as high
as 0.82 (0.81), which indicated that the genes in TGDBs
shared similar functions with those in CGC. Another
impressive result was that the POGF (nPOGF) score
f r o mT S G D Bt oC G Cw a sa sh i g ha s0 . 7 2( 0 . 7 1 )a n d
0.60 (0.59) in the other direction, although the corre-
sponding POG (nPOG) scores were very low.
All the observed POGF and nPOGF scores were statis-
tically significant (P < 1.0 E-04).
Consistency of gene lists discovered in low- and high-
throughput studies
We used the L-list for the 1208 distinct genes extracted
from the six databases that contained cancer genes dis-
covered in small-scale studies, and the H-list for the 491
cancer genes identified by mutational screening for four
cancer types [19,20,22,23]. From the L-list to the H-list,
the POG (nPOG) score was as low as 0.07 (0.05), which
indicated that most cancer genes accumulated in the
small-scale studies were not rediscovered in the high-
throughput data. From the H-list to the L-list, the score
was a little larger, but still low, at 0.16 (0.12), which
indicated that the high-throughput screening studies
could find only a small fraction of all cancer genes. For
each of the four cancer types, the consistency of the
sub-lists of cancer genes extracted from the L-list and
H-list was also very low (Table 2).
On the other hand, the POGF (nPOGF) score from
the L-list to the H-list was 0.69 (0.67) and 0.74 (0.70) in
the other direction. Thus, functionally, cancer genes
found in small-scale experiments were consistent with
those found in the high-throughput studies. As shown
in Table 2, from the sub-lists of cancer genes discovered
by the genome screening to the sub-lists of cancer genes
discovered in small-scale experiments for breast, colon
and pancreatic cancers, and glioblastoma, the POGF
(nPOGF) scores were as high as 0.62 (0.60), 0.82 (0.81),
0.62 (0.60) and 0.83 (0.83), respectively. In the other
direction, the POGF (nPOGF) scores were much lower,
Figure 1 The consistency scores between different cancer gene lists. A. The bars above the x-axis depict POG (nPOG) and POGF (nPOGF)
scores from other lists to CGC, and the bars below the x-axis depict the POG (nPOG) and POGF (nPOGF) scores from CGC to other lists. The red
lines within the bars depict the POGF scores expected by random chance. B. The POG (nPOG) and POGF (nPOGF) scores between the H-list, L-
list and R-List. The bars above the x-axis depict POG (nPOG) and POGF (nPOGF) scores from H-list to L-list, from L-list to R-list and from H-list to
R-list respectively. The bars below the x-axis depict scores from L-list to H-list, from R-list to L-list and from R-list to H-list respectively. The red
lines within the bars depict the POGF scores expected by random chance.
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(0.63) for the four cancer types, respectively. Thus, for
each cancer type, the cancer genes discovered by the
genome screening might cover more functions of cancer
genomes than the cancer genes accumulated from
small-scale experiments.
We used the R-list for the 645 cancer genes indentified
by the high-throughput retroviral insertional mutagenesis
screening. As shown in Figure 2B, the POG (nPOG) scores
from the R-list to the L-list were 0.12 (0.10) and 0.22
(0.18) in the other direction. However, the POGF
(nPOGF) scores were as high as 0.70 (0.68) and 0.78 (0.75)
in the two directions, respectively. These results were simi-
lar to those for the H-list. The POG (nPOG) score from
the R-list to the H-list was only 0.05 (0.03) and 0.04 (0.02)
in the other direction. The POGF (nPOGF) scores in the
two directions were 0.57 (0.53) and 0.62 (0.60), respec-
tively, which suggested that these two lists of cancer genes
were less functionally overlapped.
Cancer genes selected by functional consistency and the
F-Census database
Even at the functional level, some inconsistency still
existed between CGC and other databases. Therefore,
we selected genes from other lists according to their
functional similarity to genes in the CGC database.
With FDR 1% and FDR 5%, respectively, 685 and 756
genes were selected. As shown in Table 3, in most of
the 10 cancer-related pathways from Cancer Cell Map,
the selected genes were significantly enriched (P < 0.01),
whereas the remaining genes were not (P >0 . 0 1 ) .I n
these pathways, most ratios of the selected genes to the
other genes were >10, which supports the hypothesis
that the selected genes are more likely to be cancer-
associated.
Based on the above results, we have developed a data-
base named F-Census for extracting functionally consis-
tent cancer genes from different data sources. This
database is available at http://bioinfo.hrbmu.edu.cn/fcen-
sus/. Using this database, users can extract cancer genes
from several databases to obtain their union and inter-
section gene sets, thus providing information about can-
cer genes, such as their type (oncogenes and tumor
suppressor genes), their occurrence in different cancers,
and their mutation frequencies estimated from the high-
throughput studies. Also, the users can obtain the can-
cer gene list pre-selected by our criteria based on their
functional similarity to genes in CGC. The users can
upload a list of candidate genes and prioritize the genes
in the list according to their functional similarity to
Figure 2 Distribution of cancer genes in the Wnt and EGFR1 pathways. The x axis depicts the eight cancer gene lists and the y axis depicts
the overlapping genes between the genes in the eight lists and all the genes in the pathways.
Table 2 The scores between sub-lists of cancer genes for each cancer type
Tumor Gene No.
(L:H)
From L to H From H to L
POG nPOG POGF nPOGF POG nPOG POGF nPOGF
Breast 67:122
a 0.11 0.10 0.62 0.60 0.04 0.04 0.58 0.56
Colon 44:118 0.24 0.23 0.82 0.81 0.06 0.06 0.64 0.63
Pancreatic 13:44 0.36 0.35 0.62 0.60 0.10 0.10 0.34 0.32
Glioblastoma 18:50 0.37 0.37 0.83 0.83 0.10 0.10 0.64 0.63
Note:
a the number of cancer genes with PPI data for the low- and high-throughput data. All the scores are statistically significant (p values < 1.0 E-04).
Gong et al. BMC Bioinformatics 2010, 11:76
http://www.biomedcentral.com/1471-2105/11/76
Page 5 of 8cancer genes in CGC. Finally, the users can look up the
functional categories enriched with cancer genes from
various cancer gene lists (please see the Help page on
our website for details).
Discussion
In this study, we showed that current cancer gene data
sources were highly inconsistent in terms of gene over-
lapping. This suggested that the sample sizes used in
either the small-scale studies or high-throughput gen-
ome screening might be too small to provide enough
power for consistently capturing genes causally related
to the extremely heterogeneous cancer [1,12,40,41].
Nevertheless, most cancer gene lists were functionally
consistent, which indicated that they might all come
from some key pathways associated with cancer. Based
on this assumption, for a list of cancer genes, there
should be subsets of non-redundant genes that could
functionally represent the full list of genes. Actually, by
the algorithm described in additional file 1, we could
select 75 genes from GCG, which could represent all
the 377 cancer genes from CGC, in the sense that all
377 cancer genes are frequently connected to the 75
cancer genes in the PPI network (POGF score = 1). A
future study is warranted to establish whether such a
non-redundant subset of genes hints at the organization
of cancer-related functions.
The biological function of a gene can be defined at
several levels, ranging from the basic biological attri-
butes of a protein product, to the nature of physical and
regulatory interactions, membership in a given biological
pathway, and membership of a specific biological net-
work (such as a PPI sub-network) [10,11]. We could
consider that the functional consistency of gene lists
evaluated by the POGF score based on PPI links is at
the PPI network level. We could also evaluate the con-
sistency of gene lists at other functional levels. For
example, using GO terms at separate levels of the GO
hierarchy, we could evaluate the consistency of gene
lists at various levels of pathway specificity, and find the
most specific level at which the consistency changes
from high to low. To design such GO-based consistency
scores, we need to consider the limitations that GO
levels are artificially defined, and a large fraction of
genes are only annotated to general high-level terms.
It would be interesting to identify a functional level at
which cancer genes of the same cancer type overlap
strongly and cancer genes of different cancer types can
be distinguished. However, it might be difficult, if not
impossible, to achieve this goal because most genes
responsible for tumorigenesis of different cancer types
might disrupt the same or similar pathways [29]. In the
KEGG database, all the 14 pathways labelled with cancer
types, according to some so far agreed cancer-type-spe-
cific genes, such as APC of colorectal cancer, actually
consist of similar biological pathways, such as mitogen-
activated protein kinase, p53, transforming growth fac-
tor-b and Jak-Stat pathways [42]. Statistically, because of
the small samples studied for some cancers, the lists of
cancer genes accumulated so far for different cancers
might be inconsistent and insufficient for functional dis-
crimination of cancer types. As demonstrated in our
previous work [34], even for the same cancer, the true
disease markers identified in different studies with insuf-
ficient samples (and thus low statistical power) are
highly likely to be inconsistent. We believe that it might
be necessary to use more samples and combine func-
tional data with tissue expression data to study cancer-
type-specific mechanisms.
The literature-based interaction data in the HPRD
database might be biased towards well-studied cancer
genes. However, Ciccarelli et al. [6] have argued that
such a bias might be ignorable because, in the high-
throughput PPI data, cancer genes also tend to have
higher degrees in the PPI network than other genes.
Similarly, using cancer genes with both literature-based
interaction data and high-throughput interaction data in
the HPRD database, we found that the literature-based
Table 3 The enrichment of the selected genes in cancer pathways (FDR < 0.01)
Signal pathway names p values* p values** Ratios
Alpha6Beta4Integrin_pathway(54
a) 4.75E-12 0.89 24
AndrogenReceptor_pathway(103) 2.76E-11 1 Inf***
EGFR1_pathway(179) 0 0.64 10.7
Hedgehog_pathway(23) 3.41E-05 0.01 1.75
ID_pathway(25) 1.30E-10 1 Inf
KitReceptor_pathway(69) 0 0.72 16.5
NOTCH_pathway(80) 9.40E-11 0.33 5
TGFBR_pathway(159) 8.29E-13 0.69 9.8
TNFAlphaNFkb_pathway(189) 0 0.82 7.2
Wnt_pathway(105) 0 0.01 2.6
Note:
a the number of genes in the pathway;* the p value of the enrichment of the selected genes; ** the p value of the enrichment of the rest cancer genes; ***
Inf means none of the rest genes are annotated in the pathway.
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lated with their high-throughput data-based degrees (r =
0.4, P < 0.01, Spearman’s rank correlation), indicating
our functional assessment would not be severely affected
by the research bias. This problem should be further
addressed when more high-throughput PPI data become
available. Another concern that should be addressed is
that current PPI data are incomplete. However, as in the
present study, the functional similarity measure based
on indirect PPI links might lessen the effect of the
incompleteness of the direct PPI links.
In our study, CGC was employed as a benchmark for
the comparison because it is the most widely applied
data source. However, this benchmark might be biased
because genes collected in CGC tend to originate from
lymphoma/leukaemia, and most genes were of transloca-
tion mutations. Thus, in our future work, we will exploit
o t h e rc r i t e r i at od e f i n em o r er e l i a b l ea n du n b i a s e d
benchmark cancer gene sets. One approach might be to
find genes non-randomly co-mutated with other genes
in cancer samples. As implied by our work [43] and
Yeang et al. [44], this statistically sound approach could
bypass the unsolved difficulty of the background muta-
tion rate estimation in so-far used prediction methods.
Finally, we note that the F-Census database is still
under development, and is aimed at including more
comprehensive information on cancer genes. For exam-
ple, we have included in the database genes non-ran-
domly co-mutated with other genes in cancer samples,
which can provide strong statistical evidence on their
involvement and functional coordination in cancer
[9,44]. Additionally, we have collected miRNAs that
could play important roles in oncogenesis by regulating
cancer genes [45-47]. We will also try to consider the
full spectrum of genetic and epigenetic changes in can-
cer in our future studies [48,49].
Conclusions
Because cancer is an extremely heterogeneous disease,
low consistency in the discovery of cancer genes could
have been expected in studies that have used insufficient
samples. Although most data sources have low gene
overlapping, they are highly consistent at the functional
level, which indicates that they might capture separately
different genes in a few key pathways associated with
cancer. Our database provides biologists with a useful
tool for browsing and extracting functionally consistent
cancer genes from various data sources.
Additional file 1: Algorithm for finding a non-redundant gene set
from a list.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-2105-11-
76-S1.DOC]
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